Esaote unveils new ultrasound unit
Ultrasound developer Esaote, based in Genoa, Italy, introduced a new premium ultrasound device at the RSNA show. Technos is designed for abdominal, ob/gyn, vascular, small parts, breast, and urology imaging, and completes Esaote’s radiology and
Ultrasound developer Esaote, based in Genoa, Italy, introduced a new premium ultrasound device at the RSNA show. Technos is designed for abdominal, ob/gyn, vascular, small parts, breast, and urology imaging, and completes Esaotes radiology and shared service markets product line. The unit carries a fully digital beamformer and proprietary microchip circuitry, as well as new probe technology that maximizes the lateral resolution of Technos wideband multifrequency transducers. Technos combines color Doppler and power Doppler technology, and runs on a Windows NT operating system.
In other Esaote news, the company celebrated the sale of its 500th dedicated MRI system, which it has achieved through sales of both Artoscan and E-Scan, an open-style, 0.2-tesla MRI scanner dedicated to orthopedic studies. E-Scan was cleared by the Food and Drug Administration in June (SCAN 6/23/99).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
